Status: Recruiting
Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL
This is a multi-center, prospective cohort study. The main purpose of study is to evaluate the efficacy and safety of Orelabrutinib combined with Zuberitamab in the initial treatment of MZL Main efficacy indicators Complete response rate (CR) at the end of combination therapy.
Participants needed: 33
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Li ZhimingUpdated: May 22, 2025Locations: 2
Eligibility criteria
ANC>1.0×109/L; [+5]
Patients with central nervous system invasion; [+14]